← Back

Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Price · split & dividend adjusted
News & notes moving NEUP
NEUP▼

Halper Sadeh LLC Investigates Whether SAFT, NEUP, RMAX, NRIM Are Obtaining Fair Deals for Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws or breaches of fiduciary duties to shareholders. The investigations concern Safety Insurance Group Inc.'s sale to an affiliate of Mapfre S.A. for $105.00 per share in cash, Neuphoria Therapeutics Inc.'s merger with Scancell Holdings plc where Neuphoria shareholders would own 14.5% of the combined company, RE/MAX Holdings Inc.'s sale to The Real Brokerage Inc. for either 5.152 shares of the combined company or $13.80 in cash per share, and Northrim BanCorp Inc.'s merger with PBCO Financial Corporation. The firm notes that insiders may receive substantial financial benefits not available to ordinary shareholders and that the proposed transactions may contain terms limiting superior competing offers. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
NEUP ▼NRIM ▼RMAX ▼SAFT ▼0NQ2.LSE SCLP.LSE
GlobeNewswire·27dRead more ▾
NEUP

Monteverde Law Firm Investigates Mergers of Northrim Bancorp, Neuphoria Therapeutics, Safety Insurance, and RE/MAX

Class action attorney Juan Monteverde of Monteverde & Associates PC announced investigations into four proposed mergers. The firm is examining Northrim Bancorp's merger with PBCO Financial Corporation, Neuphoria Therapeutics' merger with Scancell Holdings where Neuphoria stockholders would own 11.1% of the combined company, Safety Insurance Group's sale to a Mapfre affiliate at $105.00 per share in cash, and RE/MAX Holdings' sale to The Real Brokerage where shareholders may receive 5.152 shares of the combined company or $13.80 in cash per share. The RE/MAX shareholder vote is scheduled for August 14, 2026. Monteverde & Associates PC, a national class action securities firm headquartered at the Empire State Building, has recovered millions of dollars for shareholders and was recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
NEUP NRIM RMAX SAFT SCLP.LSE
GlobeNewswire·27dRead more ▾
NEUP▲

Neuphoria confirms talks with Scancell about potential acquisition

Neuphoria Therapeutics confirmed it is in discussions with London-listed Scancell Holdings about a potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company after any deal. The statement follows an earlier announcement by Scancell about a possible combination, made after UK press speculation and in compliance with UK regulations. Neuphoria cautioned that there is no certainty an agreement will be reached, nor on the terms or whether a transaction will proceed. Any further announcements will be made in line with SEC and Nasdaq rules.
NEUP ▲SCLP.LSE ▲
GlobeNewswire·61dRead more ▾
© 2026 MarketDXAsset